Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy
Technology appraisal guidance
Reference number: TA992
Published:
We are issuing a short exceptional pause to the publication of our final guidance on this topic. The aim is to allow all parties to reach a rapid commercial solution that enables patient access to this treatment.